nach oben

Clinical and Translational Oncology

Erschienen in:

08.02.2018 | Research Article

Stromal expression of JNK1 and VDR is associated with the prognosis of esophageal squamous cell carcinoma

verfasst von: Y. Bao, S. Zhang, Y. Guo, X. Wei, Y. Zhang, Y. Yang, H. Zhang, M. Ma, W. Yang

Erschienen in: Clinical and Translational Oncology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide, and its outcome is poor. The purpose of this study was to determine the association between JNK1 and vitamin D receptor (VDR) expression and the prognosis of ESCC.

Methods

Immunohistochemical staining was conducted on ESCC tissue microarrays (362 pairs of ESCC and normal esophagus tissues). The epithelial and stromal expression levels of c-jun NH2-terminal kinase 1 (JNK1) and VDR were scored and correlated with the ESCC characteristics. Laser-capture-based quantitative RT-PCR was performed on ESCC tissues. The effects of JNK1 and VDR on ESCC cell proliferation and migration were analyzed in vitro by transient transfection, and protein changes were evaluated by immunoblotting.

Results

Both JNK1 and VDR were reduced in ESCC epithelial cells in comparison with the normal esophagus, but the expression of JNK1 and VDR in ESCC stromal tissues, not epithelial cells, was strongly associated with the survival time of ESCC patients. Functional studies showed that increased JNK1 suppressed cancer cell proliferation, mobility, and migration, which were linked to the alterations of VDR and metastasis-associated proteins.

Conclusion

JNK1 and VDR act as tumor suppressors, and their stromal expression levels are associated with prognosis in esophageal squamous cell carcinoma.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed

Wang C, Wang J, Chen Z, Gao Y, He J. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer. 2017;36:65.CrossRefPubMedPubMedCentral

Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007;19:142–9.CrossRefPubMed

Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171:24–37.CrossRefPubMed

Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X, et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol. 2012;14:1203–11.CrossRefPubMed

Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer. 2009;8:64.CrossRefPubMedPubMedCentral

Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, et al. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene. 2013;32:4231–42.CrossRefPubMed

10.

Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Investig. 2008;118:3943–53.CrossRefPubMed

11.

Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010;17:89–97.CrossRefPubMedPubMedCentral

12.

Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–52.CrossRefPubMed

13.

She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Can Res. 2002;62:1343–8.

14.

Gao Y, Tao J, Li MO, Zhang D, Chi H, Henegariu O, et al. JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance. J Immunol. 2005;175:5783–9.CrossRefPubMed

15.

Hu D, Fang W, Han A, Gallagher L, Davis RJ, Xiong B, et al. c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis. 2008;29:2317–24.CrossRefPubMedPubMedCentral

16.

Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, et al. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol. 2007;171:297–303.CrossRefPubMedPubMedCentral

17.

Buitrago CG, Ronda AC, de Boland AR, Boland R. MAP kinases p38 and JNK are activated by the steroid hormone 1alpha,25(OH)2-vitamin D3 in the C2C12 muscle cell line. J Cell Biochem. 2006;97:698–708.CrossRefPubMed

18.

Fukumori S, Murata T, Taguchi M, Hashimoto Y. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells. Drug Metab Pharmacokinet. 2007;22:377–81.CrossRefPubMed

19.

Qi X, Pramanik R, Wang J, Schultz RM, Maitra RK, Han J, et al. The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition. J Biol Chem. 2002;277:25884–92.CrossRefPubMed

20.

Slattery ML, Lundgreen A, Wolff RK. Dietary influence on MAPK-signaling pathways and risk of colon and rectal cancer. Nutr Cancer. 2013;65:729–38.CrossRefPubMedPubMedCentral

21.

Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154:369–87.CrossRefPubMedPubMedCentral

22.

Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell. 2006;21:799–809.CrossRefPubMed

23.

Li QP, Qi X, Pramanik R, Pohl NM, Loesch M, Chen G. Stress-induced c-Jun-dependent Vitamin D receptor (VDR) activation dissects the non-classical VDR pathway from the classical VDR activity. J Biol Chem. 2007;282:1544–51.CrossRefPubMed

24.

Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A, et al. Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS One. 2011;6:e23524.CrossRefPubMedPubMedCentral

25.

Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, Brasitus TA. 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. J Biol Chem. 1999;274:35505–13.CrossRefPubMed

26.

Harris DM, Go VL. Vitamin D and colon carcinogenesis. J Nutr. 2004;134:3463S–71S.CrossRefPubMed

27.

Kallay E, Bises G, Bajna E, Bieglmayer C, Gerdenitsch W, Steffan I, et al. Colon-specific regulation of vitamin D hydroxylases—a possible approach for tumor prevention. Carcinogenesis. 2005;26:1581–9.CrossRefPubMed

28.

Bi X, Shi Q, Zhang H, Bao Y, Hu D, Pohl N, et al. c-Jun NH2-teminal kinase 1 interacts with vitamin D receptor and affects vitamin D-mediated inhibition of cancer cell proliferation. J Steroid Biochem Mol Biol. 2016;163:164–72.CrossRefPubMed

29.

Guo Y, Bao Y, Ma M, Zhang S, Zhang Y, Yuan M, et al. Clinical significance of the correlation between PLCE 1 and PRKCA in esophageal inflammation and esophageal carcinoma. Oncotarget. 2017;8:33285–99.PubMedPubMedCentral

30.

Bao Y, Wang Q, Guo Y, Chen Z, Li K, Yang Y, et al. PRSS8 methylation and its significance in esophageal squamous cell carcinoma. Oncotarget. 2016;7:28540–55.PubMedPubMedCentral

31.

Bao Y, Li K, Guo Y, Wang Q, Li Z, Yang Y, et al. Tumor suppressor PRSS8 targets Sphk1/S1P/Stat3/Akt signaling in colorectal cancer. Oncotarget. 2016;7:26780–92.PubMedPubMedCentral

32.

Guo Y, Bao Y, Yang W. Regulatory miRNAs in colorectal carcinogenesis and metastasis. Int J Mol Sci. 2017;18(4):890.

33.

Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. 2014;5:2016–29.CrossRefPubMedPubMedCentral

34.

Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Investig. 2014;124:1853–67.CrossRefPubMed

35.

Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16:10.CrossRefPubMedPubMedCentral

36.

Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life. 2005;57:283–95.CrossRefPubMed

37.

Shaulian E. AP-1–The Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal. 2010;22:894–9.CrossRefPubMed

38.

Meeker S, Seamons A, Paik J, Treuting PM, Brabb T, Grady WM, et al. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Can Res. 2014;74:4398–408.CrossRef

39.

Protiva P, Cross HS, Hopkins ME, Kallay E, Bises G, Dreyhaupt E, et al. Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity. Cancer Prev Res. 2009;2:43–51.CrossRef

40.

Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421–42.CrossRefPubMed

Titel: Stromal expression of JNK1 and VDR is associated with the prognosis of esophageal squamous cell carcinoma
verfasst von: Y. Bao
S. Zhang
Y. Guo
X. Wei
Y. Zhang
Y. Yang
H. Zhang
M. Ma
W. Yang
Publikationsdatum: 08.02.2018
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 9/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1843-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Stromal expression of JNK1 and VDR is associated with the prognosis of esophageal squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Cancer and aging in Ibero-America

Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients

miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1

Integral nutritional approach to the care of cancer patients: results from a Delphi panel

Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation

Radiotherapy in soft-tissue sarcoma of the extremities

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie